Literature DB >> 31863309

Changes in heparan sulfate sulfotransferases and cell-surface heparan sulfate during SKM-1 cells granulocytic differentiation and A549 cells epithelial-mesenchymal transition.

Shancheng Zhao1, Zhen Wang2.   

Abstract

Heparan sulfate (HS) with various sulfation patterns is one of important modulators of cancer cell fate through interacting with numerous growth factors. Here we found HS 2-O sulfotransferase 1 (HS2ST1) was downregulated at both mRNA and protein levels during granulocytic differentiation of SKM-1 leukemia cells and also HS (glucosamine) 3-O sulfotransferase 3A (HS3ST3A) in epithelial-mesenchymal transition (EMT) of A549 lung cancer cells, meanwhile, cell-surface HS recognized by anti-HS antibody was also changed in both cancer cell lines. Further, HS3ST3A was negatively correlated with the in vitro cell metastasis capability of A549 cells confirmed by RNA interference technology, wound-healing assay and in vitro Matrigel invasion assay. Together, specific HS sulfotransferases may serve as molecular markers and targets for cancer treatment.

Entities:  

Keywords:  Epithelial-mesenchymal transition; Granulocytic differentiation; Heparan sulfate sulfotransferase; Metastasis; Myelodysplastic syndrome leukemia; Non-small-cell lung cancer

Year:  2019        PMID: 31863309     DOI: 10.1007/s10719-019-09903-0

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  35 in total

Review 1.  Functions of cell surface heparan sulfate proteoglycans.

Authors:  M Bernfield; M Götte; P W Park; O Reizes; M L Fitzgerald; J Lincecum; M Zako
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

Review 2.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

3.  Heparan sulfate in chronic kidney diseases: Exploring the role of 3-O-sulfation.

Authors:  Laura Ferreras; Anna Moles; Gerhard R Situmorang; Rana El Masri; Imogen L Wilson; Katie Cooke; Emily Thompson; Marion Kusche-Gullberg; Romain R Vivès; Neil S Sheerin; Simi Ali
Journal:  Biochim Biophys Acta Gen Subj       Date:  2019-02-19       Impact factor: 3.770

4.  Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes.

Authors:  Roberto Stasi; Maurizio Brunetti; Edmondo Terzoli; Sergio Amadori
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

5.  Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma.

Authors:  Masato Fujiyoshi; Atsushi Kuno; Masanori Gotoh; Moto Fukai; Hideki Yokoo; Hirofumi Kamachi; Toshiya Kamiyama; Masaaki Korenaga; Masashi Mizokami; Hisashi Narimatsu; Akinobu Taketomi
Journal:  J Gastroenterol       Date:  2015-03-15       Impact factor: 7.527

Review 6.  Heparan sulphate proteoglycans fine-tune mammalian physiology.

Authors:  Joseph R Bishop; Manuela Schuksz; Jeffrey D Esko
Journal:  Nature       Date:  2007-04-26       Impact factor: 49.962

Review 7.  Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate.

Authors:  Israel Vlodavsky; Neta Ilan; Annamaria Naggi; Benito Casu
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

8.  Role of heparan sulfate 2-o-sulfotransferase in prostate cancer cell proliferation, invasion, and growth factor signaling.

Authors:  Brent W Ferguson; Sumana Datta
Journal:  Prostate Cancer       Date:  2011-10-23

9.  Heparan sulphate synthetic and editing enzymes in ovarian cancer.

Authors:  A C Backen; C L Cole; S C Lau; A R Clamp; R McVey; J T Gallagher; G C Jayson
Journal:  Br J Cancer       Date:  2007-04-17       Impact factor: 7.640

Review 10.  The Emerging Roles of Heparan Sulfate 3-O-Sulfotransferases in Cancer.

Authors:  Agnès Denys; Fabrice Allain
Journal:  Front Oncol       Date:  2019-06-12       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.